報價延遲最少15分鐘:2026/04/21 20:02 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.51 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.25/-1.75
|
|
企業價值
593.20M
|
| 資產負債 |
|
每股賬面淨值
4.20
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGENDPhase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform. |
